高强度跑台运动对新发帕金森病运动症状的影响:2期随机临床试验
SPARX为2期多中心随机对照试验,128例未用药新发帕金森病患者随机分为高强度跑台运动、中等强度运动或等待对照,为期6个月。
要点
- 高强度跑台运动对未用药新发帕金森病患者可行且安全。
- 高强度组UPDRS运动评分变化优于对照组,达到非无效性阈值。
- 中等强度运动未达到预设非无效性阈值。
核心结论
- 高强度跑台运动对新发帕金森病患者可能可行且可安全处方,值得开展疗效试验验证临床获益。
研究设计与样本
- SPARX为2期多中心随机对照试验,纳入128例40-80岁、Hoehn-Yahr 1-2期、确诊5年内且未用药的特发性帕金森病患者。
- 患者随机分为高强度跑台运动组(n=43)、中等强度跑台运动组(n=45)或等待对照(n=40),干预6个月,评估者设盲。
主要发现
- 高强度组运动频率为每周2.8天(95%CI 2.4-3.2),心率为最大心率的80.2%(95%CI 78.8%-81.7%)。
- 高强度组达到预设非无效性阈值,中等强度组未达到。
- 预期不良肌肉骨骼事件不严重。
关键数值与推荐
- 高强度组运动处方为每周4天、最大心率80%-85%;中等强度组为每周4天、最大心率60%-65%。
- 可行性指标为坚持规定心率和每周至少3天运动频率;临床结局为6个月UPDRS运动评分变化。
临床怎么用
- 对于未用药的新发帕金森病患者,高强度跑台运动可作为可行且安全的运动处方选项。
- 中等强度运动未显示达到非无效性阈值,选择运动强度时需考虑高强度方案。
局限性
- 本研究为2期试验,主要目的是评估可行性和安全性,而非确证临床疗效。
- 样本以非西班牙裔白人为主(108/128,84.4%),结果外推需谨慎。
- 随访仅6个月,长期效果未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Parkinson disease is a progressive neurologic disorder. Limited evidence suggests endurance exercise modifies disease severity, particularly high-intensity exercise. OBJECTIVES: To examine the feasibility and safety of high-intensity treadmill exercise in patients with de novo Parkinson disease who are not taking medication and whether the effect on motor symptoms warrants a phase 3 trial. DESIGN, SETTING, AND PARTICIPANTS: The Study in Parkinson Disease of Exercise (SPARX) was a phase 2, multicenter randomized clinical trial with 3 groups and masked assessors. Individuals from outpatient and community-based clinics were enrolled from May 1, 2012, through November 30, 2015, with the primary end point at 6 months. Individuals with idiopathic Parkinson disease (Hoehn and Yahr stages 1 or 2) aged 40 to 80 years within 5 years of diagnosis who were not exercising at moderate intensity greater than 3 times per week and not expected to need dopaminergic medication within 6 months participated in this study. A total of 384 volunteers were screened by telephone; 128 were randomly assigned to 1 of 3 groups (high-intensity exercise, moderate-intensity exercise, or control). INTERVENTIONS: High-intensity treadmill exercise (4 days per week, 80%-85% maximum heart rate [n = 43]), moderate-intensity treadmill exercise (4 days per week, 60%-65% maximum heart rate [n = 45]), or wait-list control (n = 40) for 6 months. MAIN OUTCOMES AND MEASURES: Feasibility measures were adherence to prescribed heart rate and exercise frequency of 3 days per week and safety. The clinical outcome was 6-month change in Unified Parkinson's Disease Rating Scale motor score. RESULTS: A total of 128 patients were included in the study (mean [SD] age, 64 [9] years; age range, 40-80 years; 73 [57.0%] male; and 108 [84.4%] non-Hispanic white). Exercise rates were 2.8 (95% CI, 2.4-3.2) days per week at 80.2% (95% CI, 78.8%-81.7%) maximum heart rate in the high-intensity group and 3.2 (95% CI, 2.8-3.6; P = .13) days per week at 65.9% (95% CI, 64.2%-67.7%) maximum heart rate in the moderate-intensity group (P < .001). The mean change in Unified Parkinson's Disease Rating Scale motor score in the high-intensity group was 0.3 (95% CI, -1.7 to 2.3) compared with 3.2 (95% CI, 1.4 to 5.1) in the usual care group (P = .03). The high-intensity group, but not the moderate-intensity group, reached the predefined nonfutility threshold compared with the control group. Anticipated adverse musculoskeletal events were not severe. CONCLUSIONS AND RELEVANCE: High-intensity treadmill exercise may be feasible and prescribed safely for patients with Parkinson disease. An efficacy trial is warranted to determine whether high-intensity treadmill exercise produces meaningful clinical benefits in de novo Parkinson disease. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01506479.
引用
- Schenkman M, Moore CG, Kohrt WM, et al. Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 29228079. doi:10.1001/jamaneurol.2017.3517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。